These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 19729434)

  • 21. Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice.
    Kanetsuna Y; Takahashi K; Nagata M; Gannon MA; Breyer MD; Harris RC; Takahashi T
    Am J Pathol; 2007 May; 170(5):1473-84. PubMed ID: 17456755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
    Alter ML; Ott IM; von Websky K; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Klein T; Hocher B
    Kidney Blood Press Res; 2012; 36(1):119-30. PubMed ID: 23171828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.
    Ohtomo S; Ito M; Izuhara Y; Van Ypersele De Strihou C; Miyata T
    Nephrology (Carlton); 2008 Dec; 13(6):517-21. PubMed ID: 18363646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy.
    Lin M; Yiu WH; Li RX; Wu HJ; Wong DW; Chan LY; Leung JC; Lai KN; Tang SC
    Kidney Int; 2013 May; 83(5):887-900. PubMed ID: 23423259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel diabetes mellitus mouse model, MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic mice, developed severe diabetic nephropathy and improved with TCV-116 (candesartan cilexetil) treatment.
    Fujita A; Yoh K; Shimohata H; Morito N; Ojima M; Okamura M; Takahashi S; Yamagata K
    Exp Anim; 2012; 61(1):49-57. PubMed ID: 22293672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy.
    Rodionov RN; Heinrich A; Brilloff S; Jarzebska N; Martens-Lobenhoffer J; Bode-Böger SM; Todorov VT; Hugo CPM; Weiss N; Hohenstein B
    Atheroscler Suppl; 2017 Nov; 30():319-325. PubMed ID: 29096857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment of a diabetic mouse model with progressive diabetic nephropathy.
    Inada A; Nagai K; Arai H; Miyazaki J; Nomura K; Kanamori H; Toyokuni S; Yamada Y; Bonner-Weir S; Weir GC; Fukatsu A; Seino Y
    Am J Pathol; 2005 Aug; 167(2):327-36. PubMed ID: 16049320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endothelial cell-specific overexpression of endothelial nitric oxide synthase in Ins2Akita mice exacerbates diabetic nephropathy.
    Natarajan M; Habib SL; Reddick RL; Delma CR; Manickam K; Prihoda TJ; Werner SL; Mohan S
    J Diabetes Complications; 2019 Jan; 33(1):23-32. PubMed ID: 30424931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy.
    Tesch GH; Lim AK
    Am J Physiol Renal Physiol; 2011 Feb; 300(2):F301-10. PubMed ID: 21147843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insight into the genetics of diabetic nephropathy through the study of mice.
    Breyer MD; Qi Z; Tchekneva EE; Harris RC
    Curr Opin Nephrol Hypertens; 2008 Jan; 17(1):82-6. PubMed ID: 18090675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug discovery for diabetic nephropathy: trying the leap from mouse to man.
    Breyer MD
    Semin Nephrol; 2012 Sep; 32(5):445-51. PubMed ID: 23062985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of diabetic nephropathy in the Akita mouse.
    Chang JH; Gurley SB
    Methods Mol Biol; 2012; 933():17-29. PubMed ID: 22893398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy.
    Tan Y; Keum JS; Wang B; McHenry MB; Lipsitz SR; Jaffa AA
    Am J Physiol Renal Physiol; 2007 Oct; 293(4):F1026-35. PubMed ID: 17596525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What is the role of decorin in diabetic kidney disease?
    Mogyorósi A; Ziyadeh FN
    Nephrol Dial Transplant; 1999 May; 14(5):1078-81. PubMed ID: 10344340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal iron accelerates the progression of diabetic nephropathy in the HFE gene knockout mouse model of iron overload.
    Chaudhary K; Chilakala A; Ananth S; Mandala A; Veeranan-Karmegam R; Powell FL; Ganapathy V; Gnana-Prakasam JP
    Am J Physiol Renal Physiol; 2019 Aug; 317(2):F512-F517. PubMed ID: 31188032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A sensitized screen of N-ethyl-N-nitrosourea-mutagenized mice identifies dominant mutants predisposed to diabetic nephropathy.
    Tchekneva EE; Rinchik EM; Polosukhina D; Davis LS; Kadkina V; Mohamed Y; Dunn SR; Sharma K; Qi Z; Fogo AB; Breyer MD
    J Am Soc Nephrol; 2007 Jan; 18(1):103-12. PubMed ID: 17151334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy.
    Oe Y; Hayashi S; Fushima T; Sato E; Kisu K; Sato H; Ito S; Takahashi N
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1525-33. PubMed ID: 27283743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The KCa3.1 blocker TRAM34 reverses renal damage in a mouse model of established diabetic nephropathy.
    Huang C; Zhang L; Shi Y; Yi H; Zhao Y; Chen J; Pollock CA; Chen XM
    PLoS One; 2018; 13(2):e0192800. PubMed ID: 29425253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetic nephropathy: an inherited disease or just a diabetic complication?
    Berger M; Mönks D; Wanner C; Lindner TH
    Kidney Blood Press Res; 2003; 26(3):143-54. PubMed ID: 12886042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy.
    Mifsud S; Kelly DJ; Qi W; Zhang Y; Pollock CA; Wilkinson-Berka JL; Gilbert RE
    Nephron Physiol; 2003; 95(4):p83-91. PubMed ID: 14694265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.